Sexual Health Stack
PT-141 + Kisspeptin
Enhance sexual desire, arousal, and reproductive hormone optimization
Overview
A dual-pathway approach to sexual health combining melanocortin-based arousal enhancement with GnRH pulsatility optimization. PT-141 (bremelanotide) activates melanocortin-4 receptors in the brain to directly enhance sexual desire and arousal, while Kisspeptin supports the upstream hypothalamic signals that regulate reproductive hormones and natural libido.
Component Peptides
Melanocortin-4 receptor agonist — FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Acts centrally on brain arousal pathways.
GnRH pulse generator stimulant — upstream regulator of LH and FSH release, supports natural testosterone/estrogen production and sexual behavior
Expected Timeline
PT-141 effects within 45-60 minutes of dosing (acute). Kisspeptin hormonal optimization effects over 2-4 weeks of consistent use.
Safety Notes
- PT-141 commonly causes nausea (40% of users) and flushing
- PT-141 can transiently increase blood pressure — contraindicated in uncontrolled hypertension
- Maximum 8 doses of PT-141 per month per FDA labeling
- Kisspeptin may affect reproductive hormone levels — monitor in fertile individuals
- PT-141 can cause skin hyperpigmentation with repeated use
- Do not combine with PDE5 inhibitors (Viagra/Cialis) without physician guidance
Bloodwork Recommendations
- Total and free testosterone
- Estradiol
- LH and FSH
- Prolactin
- SHBG
- Comprehensive metabolic panel
- Blood pressure monitoring
Contraindications
- Uncontrolled hypertension or cardiovascular disease
- Concurrent use of other melanocortin receptor agonists
- Active hormone-sensitive cancers
- Pregnancy or breastfeeding
- Hepatic impairment (PT-141 is hepatically metabolized)
Evidence Assessment
PT-141 is FDA-approved as Vyleesi for HSDD in premenopausal women, with robust Phase III trial data. Kisspeptin has been studied in humans at Imperial College London and shown to enhance sexual brain processing and reproductive hormone release. The combination is not studied but addresses complementary pathways.
References
- Kingsberg SA, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder." Obstet Gynecol. 2019;134(5):899-908.
- Comninos AN, et al. "Kisspeptin modulates sexual and emotional brain processing in humans." J Clin Invest. 2017;127(2):709-719.
- Dhillo WS, et al. "Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males." J Clin Endocrinol Metab. 2005;90(12):6609-6615.
Research Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All products referenced are for in vitro laboratory research use only. Consult a qualified healthcare professional before beginning any research protocol.